Doxorubicin and cisplatin treatment of hepatocellular carcinoma ascites peritoneal perfusion clinical observation.docVIP

 PAGE \* MERGEFORMAT 9 Doxorubicin and cisplatin treatment of hepatocellular carcinoma ascites peritoneal perfusion clinical observation Of: Chen Chuanjie Ling-Ling Chen Xudong Wang Yan Qiao Yu [Keywords:] doxorubicin and cisplatin intraperitoneal ascites liver cancer clinical observation The treatment of primary liver cancer ascites clinical work has always been an important issue, because many are malignant ascites, and is a common complication of advanced liver cancer, previous use of systemic chemotherapy and more therapeutic paracentesis, but the results are poor, poor prognosis, patients often lead to abdominal distention due to massive ascites, respiratory difficulties, a serious impact on patient quality of life, and often due to the rapid development of large effusions caused by disease progression, the patient died within the short term. Thus, in cancer therapy to effectively control malignant ascites, to improve the quality of life of patients and prolong survival of great significance [1]. in our hospital from June 2007 to October 2008 among 50 cases of liver cancer patients with complete data doxorubicin and cisplatin intraperitoneal perfusion treatment of liver cancer ascites or conventional treatment, found that doxorubicin and cisplatin with intraperitoneal therapy in the elimination of ascites, alleviate symptoms of oppression, have achieved good results, are as follows. 1 Subjects and methods Clinical observation of the object we 1.1 June 2007 to October 2008 patients in our hospital 50 cases of Gastroenterology, liver cancer, according to the 1997 National Association for Prevention of liver cancer diagnostic criteria established by CT, B Super, MRI, AFP and comprehensive diagnostic angiography, are of primary liver cancer, and AFPgt; 600 g / mL, ascites can be seen in cancer cells. observation group of 35 cases including 25 males and 10 females, aged 37 to 73 years, mean age 54 years old. Conventional treatment for the control